Pharmacokinetics and pharmacogenetics of liposomal cytarabine in AML patients treated with CPX-351-Reference-Cited by-同舟云学术

Pharmacokinetics and pharmacogenetics of liposomal cytarabine in AML patients treated with CPX-351

Published:2021-10 Issue: Volume:338 Page:244-252
ISSN:0168-3659
Container-title:Journal of Controlled Release
language:en
Short-container-title:Journal of Controlled Release

Author:

Donnette Mélanie,Hamimed Mourad,Ciccolini Joseph,Berda-Haddad Yael,Kaspi Elise,Venton Geoffroy,Lacarelle Bruno,Costello Regis,Ouafik L'’Houcine,Farnault Laure,Fanciullino Raphaelle

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference26 articles.

1. CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties;Mayer;Int. J. Nanomedicine,2019

2. CDA as a predictive marker for life-threatening toxicities in patients with AML treated with cytarabine;Fanciullino;Blood Adv.,2018

3. High incidence of cda deficiency in patients with hematological malignancies: perspectives and therapeutic implicationS;Donnette;Ann. Oncol.,2021

4. Seek and destroy: improving PK/PD profiles of anticancer agents with nanoparticles;Rodallec;Expert. Rev. Clin. Pharmacol.,2018

5. Common Terminology Criteria for Adverse Events (CTCAE), (2021) 196.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nanotherapeutics Plus Immunotherapy in Oncology: Who Brings What to the Table?;Pharmaceutics;2022-10-28

2. Comprehensive analysis for cellular senescence-related immunogenic characteristics and immunotherapy prediction of acute myeloid leukemia;Frontiers in Pharmacology;2022-09-26

3. Determination of free and encapsulated cytarabine and daunorubicin in rat plasma after intravenous administration of liposomal formulation using ultra-high performance liquid chromatography tandem mass spectrometry;Journal of Chromatography B;2022-06

4. Cytarabine/daunorubicin;Reactions Weekly;2021-12